HRT Financial LP bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,535 shares of the biotechnology company’s stock, valued at approximately $717,000. HRT Financial LP owned about 0.07% of Aclaris Therapeutics at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of ACRS. JPMorgan Chase & Co. increased its holdings in Aclaris Therapeutics by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 44,650 shares of the biotechnology company’s stock valued at $770,000 after buying an additional 7,448 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Aclaris Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company’s stock valued at $453,000 after buying an additional 9,700 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Aclaris Therapeutics by 18.1% during the first quarter. Rhumbline Advisers now owns 55,194 shares of the biotechnology company’s stock worth $952,000 after purchasing an additional 8,469 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Aclaris Therapeutics by 44.2% during the first quarter. Allianz Asset Management GmbH now owns 81,965 shares of the biotechnology company’s stock worth $1,413,000 after purchasing an additional 25,125 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Aclaris Therapeutics by 0.4% during the first quarter. Vanguard Group Inc. now owns 2,728,820 shares of the biotechnology company’s stock worth $47,045,000 after purchasing an additional 10,713 shares during the last quarter. Hedge funds and other institutional investors own 95.33% of the company’s stock.
Insider Activity at Aclaris Therapeutics
In other news, CEO Douglas J. Manion acquired 6,500 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, March 9th. The stock was purchased at an average price of $7.74 per share, for a total transaction of $50,310.00. Following the completion of the transaction, the chief executive officer now directly owns 6,500 shares in the company, valued at $50,310. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.70% of the stock is owned by insiders.
Aclaris Therapeutics Stock Up 1.0 %
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last announced its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.75 million. Aclaris Therapeutics had a negative net margin of 312.32% and a negative return on equity of 46.40%. The firm’s revenue was up 66.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) earnings per share. Analysts expect that Aclaris Therapeutics, Inc. will post -1.81 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the company. StockNews.com assumed coverage on Aclaris Therapeutics in a report on Thursday, May 18th. They set a “sell” rating on the stock. BTIG Research dropped their price objective on Aclaris Therapeutics from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $38.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, February 7th. The Goldman Sachs Group decreased their target price on shares of Aclaris Therapeutics from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, March 7th. Finally, HC Wainwright decreased their target price on shares of Aclaris Therapeutics from $50.00 to $43.00 and set a “buy” rating for the company in a research note on Tuesday, March 7th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.00.
Aclaris Therapeutics Profile
Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.
Featured Stories
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
- Salesforce: Time to Snap it Up as the Market Buys the Dip?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
